World Heart Federation

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Retrieved on: 
Tuesday, April 2, 2024
Hypertrophy, Heart, CRDL, Patient, Mayo Clinic, PPAR, Agent handling, Cleveland Clinic, Fibrosis, European, Therapy, Myocarditis, Analysis, American Heart Association, Human, Massachusetts General Hospital, Pericarditis, MMT, Heart failure, American College, Safety, ODD, Cardiology, Clinical professor, Disease, Pericardium, Research, World Heart Federation, Management, University, Death, Pericardial effusion, Maverick, Reactive oxygen species, TSX, Priority review, FDA, Conversation, Financial statement, Inflammation, Fast Track, Calcium, Wound healing, API, Pharmaceutical industry

"Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.

Key Points: 
  • "Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
  • In January 2023, Cardiol announced the first patient had been enrolled in the Company's Phase II open-label pilot study ("MAvERIC-Pilot") investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis.
  • In November 2023, Cardiol announced that it had exceeded 50% of the patient enrollment target for the MAvERIC-Pilot study.
  • In January 2024, Cardiol announced that ARCHER had exceeded 50% patient enrollment and was progressing ahead of the original study timeline.

PlaqueTec recruits first ten patients in BIOPATTERN trial

Retrieved on: 
Wednesday, November 29, 2023
Stem Cells, Medical Supplies, Practice Management, FDA, Physical Therapy, Diabetes, Managed Care, General Health, Other Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Hospitals, Health Technology, Biometrics, Genetics, Fitness & Nutrition, Cardiology, Biotechnology, Health, Safety, Mallinckrodt, Royal Bournemouth Hospital, MHRA, Disease, World Heart Federation, Risk, Protein, CAD, Patient, Medicine, Research fellow, Death, NHS, Bristol Royal Infirmary, LBS, Royal Papworth Hospital, Coronary artery disease, Harvard Medical School, CVD, Health care, Liquid biopsy, JACC, Pharmaceutical industry, Medical imaging, Medical device

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

Key Points: 
  • PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
  • The BIOPATTERN trial will use PlaqueTec’s proprietary blood sampling device, the Liquid Biopsy System™ (LBS), to collect samples at multiple sites along a patient’s diseased coronary artery.
  • Thousands of proteins and other blood molecules will be measured in each sample, enabling the assessment of trans-plaque gradients between samples.
  • The trial aims to recruit 300 patients with established CAD who have been scheduled for a coronary angiogram.

Malaysia's Fight Against Cardiovascular Disease

Retrieved on: 
Friday, October 6, 2023
Cardiovascular disease, Health, Bukit Tinggi Medical Centre, Hospital, CHIP, Silver, Risk, Tourism, Bandar Sunway, Operation, Interventional cardiology, CVD, World Health Organization, CT, Growth, Consultant, World Heart Federation, Infection, Complex, City, PCSK9, Patient, Fatality, Medical device, Medical imaging

KUALA LUMPUR, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Cardiovascular diseases (CVDs) present a substantial global health concern, and Malaysia, is not immune to this health issue. As reported by the World Health Organization, CVDs contribute to nearly 25% of all fatalities in the country. However, the silver lining lies in early detection, which can potentially prevent fatal outcomes. To aid in the early identification of potential CVDs, five hospitals in Malaysia, namely, Bukit Tinggi Medical Centre (BTMC) in Klang, Selangor; Cardio Vascular Sentral Kuala Lumpur (CVSKL) in Kuala Lumpur; Mahkota Heart Centre in Melaka; and Sunway Medical Centre in Selangor, have adopted innovative screening procedures as part of their commitment to advancing cardiovascular health in the country.

Key Points: 
  • Dr. Yew Kuan Leong, Consultant Cardiologist at BTMC, stresses the importance of early cardiac screening and appropriate prevention in the fight against heart disease.
  • "Elevated LDL-Cholesterol levels is a major risk factor for heart disease and can remain high despite adequate oral cholesterol-lowering drugs.
  • “We believe actively involving patients in their own well-being plays an important role in ensuring good long-term cardiovascular health.
  • This fusion of healthcare and tourism makes Malaysia the ultimate destination for cardiovascular treatment and memorable travel experiences.

Malaysia's Fight Against Cardiovascular Disease

Retrieved on: 
Wednesday, October 4, 2023
Infection, World Heart Federation, CVD, CT, Tourism, Consultant, Silver, Fatality, Bukit Tinggi Medical Centre, Interventional cardiology, CHIP, Hospital, Operation, Patient, Bandar Sunway, Risk, PCSK9, Growth, City, Health, Cardiovascular disease, World Health Organization, Complex, Medical device, Medical imaging

Dr. Yew Kuan Leong, Consultant Cardiologist at BTMC, stresses the importance of early cardiac screening and appropriate prevention in the fight against heart disease.

Key Points: 
  • Dr. Yew Kuan Leong, Consultant Cardiologist at BTMC, stresses the importance of early cardiac screening and appropriate prevention in the fight against heart disease.
  • “Elevated LDL-Cholesterol levels is a major risk factor for heart disease and can remain high despite adequate oral cholesterol-lowering drugs.
  • “We believe actively involving patients in their own well-being plays an important role in ensuring good long-term cardiovascular health.
  • This fusion of healthcare and tourism makes Malaysia the ultimate destination for cardiovascular treatment and memorable travel experiences.

British Heart Foundation Features Breakthrough Heart Attack Prevention Technology in Online News Programme for World Heart Day

Retrieved on: 
Friday, September 29, 2023
Inflammation, World Heart Federation, Heart, CT, Plaque, University, Shinobu Kokoro: Hidden Heart, BHF, Cardiovascular disease, Splenic infarction, British Heart Foundation, Research, ITN, Great Western Hospital, HIV disease progression rates, Patient, Barbara Cartland bibliography, Mortality, Coronary artery disease, Great Western Hospitals NHS Foundation Trust, Death, Disease, Medical imaging, Pharmaceutical industry

OXFORD, England, Sept. 29, 2023 /PRNewswire/ -- On World Heart Day, Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, confirms that its CaRi-Heart® technology has been featured as part of a British Heart Foundation (BHF) programme anchored by presenter and journalist Louise Minchin on ITN Business  (link to CaRi-Heart segment or watch the entire programme). The CaRi-Heart technology, which was developed with funding from the BHF, harnesses artificial intelligence (AI) to analyze images of the heart arteries and predict the likelihood of a heart attack – based on information that is not otherwise available using current diagnostic techniques.

Key Points: 
  • On this year's World Heart Day, the British Heart Foundation launches The Hidden Heart programme to explore hidden heart conditions, innovations in research and new treatments.
  • The programme features Caristo's CaRi-Heart technology, with insights from the technology's scientific inventor as well as a clinical user and a patient.
  • The Hidden Heart programme interviewed one of Dr. Hyde's patients, who received CaRi-Heart results twice during the last few years.
  • British Heart Foundation was one of the earliest supporters of Professor Antoniades' research to predict heart attacks years before they happen.

British Heart Foundation Features Breakthrough Heart Attack Prevention Technology in Online News Programme for World Heart Day

Retrieved on: 
Friday, September 29, 2023
Inflammation, World Heart Federation, Heart, CT, Plaque, University, Shinobu Kokoro: Hidden Heart, BHF, Cardiovascular disease, Splenic infarction, British Heart Foundation, Research, ITN, Great Western Hospital, HIV disease progression rates, Patient, Barbara Cartland bibliography, Mortality, Coronary artery disease, Great Western Hospitals NHS Foundation Trust, Death, Disease, Medical imaging, Pharmaceutical industry

OXFORD, England, Sept. 29, 2023 /PRNewswire/ -- On World Heart Day, Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, confirms that its CaRi-Heart® technology has been featured as part of a British Heart Foundation (BHF) programme anchored by presenter and journalist Louise Minchin on ITN Business  (link to CaRi-Heart segment or watch the entire programme). The CaRi-Heart technology, which was developed with funding from the BHF, harnesses artificial intelligence (AI) to analyze images of the heart arteries and predict the likelihood of a heart attack – based on information that is not otherwise available using current diagnostic techniques.

Key Points: 
  • On this year's World Heart Day, the British Heart Foundation launches The Hidden Heart programme to explore hidden heart conditions, innovations in research and new treatments.
  • The programme features Caristo's CaRi-Heart technology, with insights from the technology's scientific inventor as well as a clinical user and a patient.
  • The Hidden Heart programme interviewed one of Dr. Hyde's patients, who received CaRi-Heart results twice during the last few years.
  • British Heart Foundation was one of the earliest supporters of Professor Antoniades' research to predict heart attacks years before they happen.

#UseHeart movement rallies for change as heart disease continues to claim most lives

Retrieved on: 
Friday, September 29, 2023
Workforce, World Heart Federation, Heart, Telehealth, Private sector, Partnership, Heart failure, Prevalence, Friends, Stroke, Parent, Policy, Sleep, WHF, CVD, Movement, Guinness World Records, WHD, Blood, Boehringer Ingelheim, Recreation, Guinness, Moyamoya disease, Lifestyle, Diagnosis, Health, Rest, Dietary supplement, Pharmaceutical industry, Laboratoires Servier

The global #UseHeart movement springs from the annual World Heart Day campaign to drive year-long awareness and action to reverse the debilitating impacts of CVD.

Key Points: 
  • The global #UseHeart movement springs from the annual World Heart Day campaign to drive year-long awareness and action to reverse the debilitating impacts of CVD.
  • Professor Daniel J. Piñeiro, President of WHF said: "The figures are so staggering that in 2013, ischaemic heart disease featured in the Guinness Book of World Records.
  • CVD prevalence can be traced to gaps in care systems, variable access to prevention, diagnosis, and treatment.
  • "Through World Heart Day and the year-long #UseHeart movement, the World Heart Federation reaches more than 2 billion people every year.

#UseHeart movement rallies for change as heart disease continues to claim most lives

Retrieved on: 
Friday, September 29, 2023
Workforce, World Heart Federation, Heart, Telehealth, Private sector, Partnership, Heart failure, Prevalence, Friends, Stroke, Parent, Policy, Sleep, WHF, CVD, Movement, Guinness World Records, WHD, Blood, Boehringer Ingelheim, Recreation, Guinness, Moyamoya disease, Lifestyle, Diagnosis, Health, Rest, Dietary supplement, Pharmaceutical industry, Laboratoires Servier

The global #UseHeart movement springs from the annual World Heart Day campaign to drive year-long awareness and action to reverse the debilitating impacts of CVD.

Key Points: 
  • The global #UseHeart movement springs from the annual World Heart Day campaign to drive year-long awareness and action to reverse the debilitating impacts of CVD.
  • Professor Daniel J. Piñeiro, President of WHF said: "The figures are so staggering that in 2013, ischaemic heart disease featured in the Guinness Book of World Records.
  • CVD prevalence can be traced to gaps in care systems, variable access to prevention, diagnosis, and treatment.
  • "Through World Heart Day and the year-long #UseHeart movement, the World Heart Federation reaches more than 2 billion people every year.

Global Heart Hub announces the launch of new patient-led research to bring attention to unhealthy cholesterol levels

Retrieved on: 
Monday, August 28, 2023
Mended Hearts, Cholesterol, World Heart Federation, Human, Science, European Society of Cardiology, Congress, Novartis, ASCVD, Moyamoya disease, ESC, Associazione Italiana Guide e Scouts d'Europa Cattolici, Pharmaceutical industry

GALWAY, Ireland, Aug. 28, 2023 /PRNewswire/ -- Following the unveiling in 2022 of Global Heart Hub's Global Cholesterol Action Plan, supported by the World Heart Federation, community support has grown to 70 patient organisations and groups who together are calling for global action to reduce the impact of unhealthy cholesterol levels. To reinforce this call to action, Global Heart Hub will begin to collect patient insights from individuals whose cholesterol levels are not at target or those who have suffered a cardiovascular event to better understand patient experiences that can help impact care and improve outcomes. The first-of-its-kind cholesterol patient insights generation by the cardiovascular patient community is needed to help support the local implementation of the Global Cholesterol Action Plan and to drive strategies to manage unhealthy cholesterol, a critical modifiable risk factor for the world's biggest killer, atherosclerotic cardiovascular disease (ASCVD)1.

Key Points: 
  • This announcement comes during the 2023 European Society of Cardiology (ESC) Congress, under the theme of 'joining forces to protect the heart'.
  • GALWAY, Ireland, Aug. 28, 2023 /PRNewswire/ -- Following the unveiling in 2022 of Global Heart Hub's Global Cholesterol Action Plan , supported by the World Heart Federation, community support has grown to 70 patient organisations and groups who together are calling for global action to reduce the impact of unhealthy cholesterol levels.
  • Neil Johnson, Executive Director, Global Heart Hub said: "While we've advanced with science and treatment, ASCVD remains the world's number one killer, with unhealthy cholesterol levels as the main culprit.
  • Representing the voice of the global patient community, the Global Cholesterol Action Plan was created with the support of Invisible Nation , a program co-created by Global Heart Hub and Novartis to expose the realities of ASCVD.

Global Heart Hub announces the launch of new patient-led research to bring attention to unhealthy cholesterol levels

Retrieved on: 
Monday, August 28, 2023
Mended Hearts, Cholesterol, World Heart Federation, Human, Science, European Society of Cardiology, Congress, Novartis, ASCVD, Moyamoya disease, ESC, Associazione Italiana Guide e Scouts d'Europa Cattolici, Pharmaceutical industry

GALWAY, Ireland, Aug. 28, 2023 /PRNewswire/ -- Following the unveiling in 2022 of Global Heart Hub's Global Cholesterol Action Plan, supported by the World Heart Federation, community support has grown to 70 patient organisations and groups who together are calling for global action to reduce the impact of unhealthy cholesterol levels. To reinforce this call to action, Global Heart Hub will begin to collect patient insights from individuals whose cholesterol levels are not at target or those who have suffered a cardiovascular event to better understand patient experiences that can help impact care and improve outcomes. The first-of-its-kind cholesterol patient insights generation by the cardiovascular patient community is needed to help support the local implementation of the Global Cholesterol Action Plan and to drive strategies to manage unhealthy cholesterol, a critical modifiable risk factor for the world's biggest killer, atherosclerotic cardiovascular disease (ASCVD)1.

Key Points: 
  • This announcement comes during the 2023 European Society of Cardiology (ESC) Congress, under the theme of 'joining forces to protect the heart'.
  • GALWAY, Ireland, Aug. 28, 2023 /PRNewswire/ -- Following the unveiling in 2022 of Global Heart Hub's Global Cholesterol Action Plan , supported by the World Heart Federation, community support has grown to 70 patient organisations and groups who together are calling for global action to reduce the impact of unhealthy cholesterol levels.
  • Neil Johnson, Executive Director, Global Heart Hub said: "While we've advanced with science and treatment, ASCVD remains the world's number one killer, with unhealthy cholesterol levels as the main culprit.
  • Representing the voice of the global patient community, the Global Cholesterol Action Plan was created with the support of Invisible Nation , a program co-created by Global Heart Hub and Novartis to expose the realities of ASCVD.